- Home
- BCG vs OMGA Comparison
BCG vs OMGA Comparison
Compare BCG & OMGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- OMGA
- Stock Information
- Founded
- BCG 2016
- OMGA 2017
- Country
- BCG United States
- OMGA United States
- Employees
- BCG N/A
- OMGA N/A
- Industry
- BCG
- OMGA Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- OMGA Health Care
- Exchange
- BCG Nasdaq
- OMGA Nasdaq
- Market Cap
- BCG 45.6M
- OMGA 53.6M
- IPO Year
- BCG N/A
- OMGA 2021
- Fundamental
- Price
- BCG $2.58
- OMGA $0.89
- Analyst Decision
- BCG
- OMGA Strong Buy
- Analyst Count
- BCG 0
- OMGA 5
- Target Price
- BCG N/A
- OMGA $9.20
- AVG Volume (30 Days)
- BCG 76.8K
- OMGA 273.1K
- Earning Date
- BCG 11-14-2024
- OMGA 11-14-2024
- Dividend Yield
- BCG N/A
- OMGA N/A
- EPS Growth
- BCG N/A
- OMGA N/A
- EPS
- BCG N/A
- OMGA N/A
- Revenue
- BCG $161,721,000.00
- OMGA $8,095,000.00
- Revenue This Year
- BCG N/A
- OMGA $181.29
- Revenue Next Year
- BCG N/A
- OMGA N/A
- P/E Ratio
- BCG N/A
- OMGA N/A
- Revenue Growth
- BCG N/A
- OMGA 185.04
- 52 Week Low
- BCG $1.85
- OMGA $0.75
- 52 Week High
- BCG $16.61
- OMGA $6.30
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- OMGA 45.10
- Support Level
- BCG N/A
- OMGA $0.83
- Resistance Level
- BCG N/A
- OMGA $1.02
- Average True Range (ATR)
- BCG 0.00
- OMGA 0.10
- MACD
- BCG 0.00
- OMGA 0.01
- Stochastic Oscillator
- BCG 0.00
- OMGA 42.31
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About OMGA Omega Therapeutics Inc.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.